fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Nike Q1 Earnings Slightly Exceeds Estimates – Stays Positive On Q2 Growth – $NKE $DIA $INVO

By John F. Heerdink, Jr.

As per reports, Nike Inc’s (NKE) first-quarter earnings exceeded market estimates, however, gross margins dropped as inventories jumped. The sportswear giant reported a 20% drop in earnings to 93 cents a share. Revenue grew 4% to $12.69 billion. Analysts were expecting Nike earnings to fall 21% to 92 cents per share, and revenue was seen climbing slightly to $12.28 billion, up from $12.25 billion last summer.

Nike’s China sales dropped 16% over the year to $1.65 billion for the period but were still in line with estimates. While North American revenue increased 15% to $5.5 billion, driven by a 17% increase in shoe sales. The majority of sales came from its European, Middle East, and Africa segments with sales increasing by 23%. However, Nike noted gross margin fell sharply versus a year earlier to 44.3% driven by higher logistics costs.

For the second-quarter Nike expects reported revenue to grow in the low double digits. For fiscal 2023, Nike predicts low-to-mid single-digit revenue growth.

NIKE, Inc. (NKE) is the world’s top designer, marketer, and distributor of athletic footwear, equipment, apparel, and accessories. The Beaverton, Oregon-based company offers products for a wide variety of sports and fitness activities. To learn more about NIKE, Inc. (NIKE) and to continue to track its progress please visit the Vista Partners NIKE Coverage Page.

 
 
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
 
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
 
 
Today, the global fertility market is a multi-million dollar market that is predicted to hit around US$47.9 billion by 2030, yet remains severely underserved with experts’ estimates suggesting that more than 90% of couples in need of infertility treatment are going without care.



On September 29th, a study, titled “Comparison of Treatment Outcomes among Sibling Oocytes Using Different Culture Systems—Conventional IVF versus INVOcell Device—And Evaluation of INVOcell User Satisfaction: The INVOcIVF Study,” was published in the International Journal of Environmental Research and Public Health. The study was conducted by Advanced Reproductive Centre (ARC), at Hospital Canselor Tuanku Muhriz (HCTM), at the National University of Malaysia, from January 2021 to January 2022.  Review the entire published study here:  “Comparison of Treatment Outcomes among Sibling Oocytes Using Different Culture Systems—Conventional IVF versus INVOcell Device—And Evaluation of INVOcell User Satisfaction: The INVOcIVF Study,”

KEY FINDINGS OF THE STUDY INCLUDED:


  • The fertilization rate and good embryo quality were comparable (not significantly different) between INVOcell and cIVF.
  • Although both methods produce similar fertilization rates and good-quality embryos, the blastulation rates were better in the INVOcell group.
  • INVOcell can be used as an alternative method for reproductive treatment in carefully selected patients without jeopardizing outcomes.
  • cIVF is costly and not applicable in most rural and district areas, therefore, the INVOcell can be utilized as a cost-effective alternative to cIVF without sacrificing comfort and outcomes.




INVO Bioscience, Inc. (Nasdaq: INVO), a commercial-stage fertility company, is dedicated to expanding the assisted reproductive technology (“ART”) marketplace by making fertility care accessible and inclusive to people around the world. Their flagship product is INVOcell®, a revolutionary medical device (pictured below) that allows fertilization and early embryo development to take place in vivo within the woman’s body. This treatment solution is the world’s first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. This technique, designated as “IVC”, provides patients a more natural, intimate, and more affordable experience in comparison to other ART treatments. INVO believes that the IVC procedure can deliver comparable results at a fraction of the cost of traditional in vitro fertilization (“IVF”) and is a significantly more effective treatment than intrauterine insemination (“IUI”). Their commercialization strategy is currently focused on the opening of dedicated “INVO Centers” offering the INVOcell® and IVC procedure (with three centers in North America now operational), continuing to distribute and sell their technology solution into existing fertility clinics, & is now actively seeking to acquire accretive acquisitions of established fertility clinics in the U.S.


INVO’s ACCRETIVE ACQUISITION STRATEGY INITIATED

INVO has announced its intention to opportunistically pursue acquisitions of established fertility clinics in the U.S. (Approx. +460 clinics operate in the U.S.) to complement its existing strategy of opening new INVO Centers and to accelerate growth. Since regaining control of INVOcell’s distribution in the U.S. earlier in 2022, INVO has engaged with over one hundred domestic IVF clinics. These interactions have reportedly yielded renewed interest in the adoption of INVOcell and the IVC procedure in existing clinics, led to new INVO Center partnership discussions and generated potential acquisition opportunities. INVO reported this week that a growing number of like-minded physicians that share INVO’s mission to democratize fertility care are now in discussions with the Company to join forces in expanding access to treatment.

INVO believes that acquisitions represent a logical extension of the Company’s strategy, as INVO looks to integrate profitable businesses run by established and successful physicians. Furthermore, acquisitions would allow INVO the opportunity to fully implement INVOcell and the IVC procedure within an acquired IVF center, which, in turn, would help to support the Company’s distribution business.

In the pursuit of an acquisition strategy, INVO is entertaining potential acquisitions and recently signed a non-binding letter for one specific opportunity. INVO and the key principals are working to consummate the acquisition and are developing a plan to incorporate INVOcell and the IVC procedure into the clinic’s existing operations with a goal of further growing revenue and earnings. Such implementation is not expected to require significant investment since IVC procedures can be added without additional equipment, space and/or human resources.

***INVO also has executed a non-binding letter of intent with a lender to provide non-dilutive funding payable to close the transaction.

 
 

Steve Shum, CEO of INVO Bioscience (NASDAQ: INVO)


“During the last few months, we have focused on driving improved operational performance at our existing INVO Centers and advancing the opening of new locations, while simultaneously exploring acquisition opportunities that would help add immediate and significant scale to our overall operations and accelerate our path to profitability.

In our existing clinics, we continue to see growing volume in patient inquiries and consultations, a leading indicator of future IVC cycles. Based on current cycle expectations, we are anticipating third quarter clinic revenue to increase significantly compared to our second quarter results.

We are actively working within our U.S. distribution business and with international partners to enhance end-market awareness and to obtain necessary regulatory approval in key markets, such as China.

On the acquisition front, we are excited by the prospect of bringing one or more established and profitable fertility centers into our operations. The practitioners we are in discussion with share our vision of leveraging the INVOcell solution to expand access to fertility and agree with our position that IVF and IVC are complementary to one another.

– – Steve Shum, CEO of INVO Bioscience (NASDAQ: INVO).

 
 

 

INVO GAINING MEDIA ATTENTION



 
INVO Bioscience’s INVO Centers and INVOcell system are beginning to gain traction with media. See Dr. Karen Hammond, the director of INVO’s Innovative Fertility Specialists (IFS) INVO Center located in Biringham, AL on set with Nicole Allshouse at FOX6 in Birmingham. 
 
 

 

INVO’s PHYSICIANS ARE GAINING RECOGNITION

On Sept 22, INVO announced that Dr. Sue Ellen Carpenter of Bloom Fertility, the Company’s Atlanta-based INVO Center, was named a recipient of the Castle Connolly Top Doctor Award for 2023. Castle Connolly Top Doctor recipients are nominated by fellow physicians and other healthcare leaders around the country identifying doctors that embody excellence in clinical care as well as interpersonal skills such as listening and communicating, demonstrating empathy and instilling trust and confidence in patients. Dr. Carpenter has been a recipient of the merit-based Castle Connolly Top Doctor Award since 2018.
(Read Original Story: Nike Earnings Narrowly Beat But NKE Stock Plunges On Soaring Inventories, Weak Margins in Investor's Business Daily)


YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us